Amebiasis Vaccine

Hikmah, Zahrotul (2022) Amebiasis Vaccine. International Journal of Science and Research (IJSR), 11 (9). pp. 202-203. ISSN 2319-7064

PDF Zahrotul Hikmah_114118528.pdf - Published Version Download (232kB)

Abstract

Amebiasis is still a major health problemin the world, especially in developing countries, low income, poor sanitation, lack of clean water, such as South Africa, Bangladesh, and Vietnam. Entamoeba histolytica is a major agent of amebiasis. Protoza intestinal parasites have caused dysentery and liver abscesses (Quach, Jeanie et al., 2014). When E.histolytica invade the intestinal epithelium, it will activate an immune response in a human host. To survive in a human host, E.histolytica repression of the host immune system and environmental control parasites. For example, when E.histolytica survive in vascular and liver environment contains a lot of oxygen, E.histolytica must subvert detection by antibodies and complement. This is against oxidative and nitrosative attack. The mucosal lining of the digestive tract generally serves as a major physical barrier against intestinal pathogens and secondary defense against the immune response of E. histolytica infection. Mucosal immunoglobulin (Ig) is a major component of the human intestinal defense mechanisms. Among them, IgA is one of the most abundant Ig produced by plasma cells (N.Kumiko-Tsukui and Tomoyoshi N, 2016).

Item Type:	Article
Uncontrolled Keywords:	Amebiasis, Vaccine, Entamoeba histolytica
Subjects:	R Medicine > RS Pharmacy and materia medica
Divisions:	Faculty of Pharmacy > Department of Pharmacy
Depositing User:	ZAHROTUL HIKMAH
Date Deposited:	09 Sep 2022 10:45
Last Modified:	09 Sep 2022 10:45
URI:	http://repository.ubaya.ac.id/id/eprint/42505

Actions (login required)

View Item